IP Library › Granted Patent US 12,545,735
Granted Patent B2
US 12,545,735 · App. 17/411,569 · Granted Feb 10, 2026

Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof

Inventors: Robert Babb (River Edge, NJ); Gang Chen (Yorktown Heights, NY); Christopher Daly (New York, NY); John DaSilva (Somers, NY); Douglas MacDonald (New York, NY); Thomas Nittoli (Pearl River, NY)
Assignee: REGENERON PHARMACEUTICALS, INC.
C07K16/2863A61K31/537A61K47/68033A61K47/6849A61K47/6857A61K47/6863A61K47/6879A61K47/6889A61P35/00C07K16/3023C07K16/3046C07K2317/31C07K2317/34C07K2317/35C07K2317/565C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,545,735
App. No.
17/411,569
Granted
Feb 10, 2026
Kind
B2
Abstract

Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.

Claims (45)

1 . A bispecific antigen-binding molecule comprising:

a first antigen-binding domain (D1) that specifically binds a first epitope of human MET; and

a second antigen-binding domain (D2) that specifically binds a second epitope of human MET;

wherein D1 comprises a heavy chain variable region (HCVR) comprising an amino acid sequence of SEQ ID NO: 58 with no more than two amino acid substitutions, and a light chain variable region (LCVR) comprising an amino acid sequence of SEQ ID NO: 138 with no more than two amino acid substitutions, wherein heavy chain complementarity determining region (HCDR) amino acid residues and light chain complementarity determining region (LCDR) amino acid residues are unsubstituted; and

wherein D2 comprises a heavy chain variable region (HCVR) comprising an amino acid sequence of SEQ ID NO: 82 with no more than two amino acid substitutions, and a light chain variable region (LCVR) comprising an amino acid sequence of SEQ ID NO: 138 with no more than two amino acid substitutions, wherein heavy chain complementarity determining region (HCDR) amino acid residues and light chain complementarity determining region (LCDR) amino acid residues are unsubstituted.

2 . The bispecific antigen-binding molecule of claim 1 , wherein D1 comprises an HCVR having an amino acid sequence of SEQ ID NO: 58 with no more than one amino acid substitution and an LCVR having an amino acid sequence of SEQ ID NO: 138 with no more than one amino acid substitution.

3 . The bispecific antigen-binding molecule of claim 1 , wherein D1 comprises an HCVR/LCVR amino acid sequence pair comprising SEQ ID NOs: 58/138 with no more than one amino acid substitution.

4 . The bispecific antigen-binding molecule of claim 1 , wherein D1 comprises an HCVR comprising the amino acid sequence of SEQ ID NO:58; and an LCVR comprising the amino acid sequence of SEQ ID NO:138.

5 . The bispecific antigen-binding molecule of claim 1 , wherein D2 comprises an HCVR having an amino acid sequence of SEQ ID NO: 82 with no more than one amino acid substitution and an LCVR of SEQ ID NO: 138 with no more than one amino acid substitution.

6 . The bispecific antigen-binding molecule of claim 1 , wherein D2 comprises an HCVR/LCVR amino acid sequence pair comprising SEQ ID NOs: 82/138 with no more than one amino acid substitution.

7 . The bispecific antigen-binding molecule of claim 1 , wherein D2 comprises an HCVR comprising the amino acid sequence of SEQ ID NO:82; and an LCVR comprising the amino acid sequence of SEQ ID NO:138.

8 . The bispecific antigen-binding molecule of claim 1 , wherein the bispecific antigen-binding molecule is conjugated to a cytotoxin.

9 . The bispecific antigen-binding molecule of claim 8 , wherein the cytotoxin is selected from the group consisting of biotoxins, chemotherapeutic agents, and radioisotopes.

10 . The bispecific antigen-binding molecule of claim 8 , wherein the cytotoxin is selected from the group consisting of maytansinoids, auristatins, duocarmycins, 225 Ac, 227 Th, and any derivatives thereof.

11 . The bispecific antigen-binding molecule of claim 1 , wherein the bispecific antigen-binding molecule is conjugated to a cytotoxic agent through a linker.

12 . The bispecific antigen-binding molecule of claim 11 , wherein the cytotoxic agent is a maytansinoid.

13 . The bispecific antigen-binding molecule of claim 12 , wherein the maytansinoid is:

wherein the - is the bond to the linker.

14 . The bispecific antigen-binding molecule of claim 13 , wherein the linker is:

wherein the bond noted with represents the bond to the bispecific antigen-binding molecule and the bond noted with represents the bond to the maytansinoid.

15 . The bispecific antigen-binding molecule of claim 12 , wherein the maytansinoid is

wherein the - in is the bond to the linker.

16 . The bispecific antigen-binding molecule of claim 15 , wherein the linker is:

wherein the bond noted with represents the bond to the bispecific antigen-binding molecule and the bond noted with represents the bond to the maytansinoid.

17 . A pharmaceutical composition comprising the bispecific antigen-binding molecule of claim 1 , and a pharmaceutically acceptable carrier.

18 . The pharmaceutical composition of claim 17 , wherein D1 comprises an HCVR having an amino acid sequence of SEQ ID NO: 58 with no more than one amino acid substitution and an LCVR having an amino acid sequence of SEQ ID NO: 138 with no more than one amino acid substitution.

19 . The pharmaceutical composition of claim 17 , wherein D1 comprises an HCVR/LCVR amino acid sequence pair comprising SEQ ID NOs: 58/138 with no more than one amino acid substitution.

20 . The pharmaceutical composition of claim 17 , wherein D1 comprises an HCVR comprising the amino acid sequence of SEQ ID NO:58; and an LCVR comprising the amino acid sequence of SEQ ID NO:138.

21 . The pharmaceutical composition of claim 17 , wherein D2 comprises an HCVR comprising the amino acid sequence of SEQ ID NO:82, and an LCVR comprising the amino acid sequence of SEQ ID NO:138, wherein HCDR amino acid residues and LCDR amino acid residues are unsubstituted.

22 . The pharmaceutical composition of claim 17 , wherein D2 comprises an HCVR having an amino acid sequence of SEQ ID NO: 82 with no more than one amino acid substitution and an LCVR of SEQ ID NO: 138 with no more than one amino acid substitution.

23 . The pharmaceutical composition of claim 17 , wherein D2 comprises an HCVR/LCVR amino acid sequence pair comprising SEQ ID NOs: 82/138 with no more than one amino acid substitution.

24 . The pharmaceutical composition of claim 17 , wherein D2 comprises an HCVR comprising the amino acid sequence of SEQ ID NO:82; and an LCVR comprising the amino acid sequence of SEQ ID NO:138.

25 . The pharmaceutical composition of claim 17 , wherein the bispecific antigen-binding molecule is conjugated to a cytotoxin.

26 . The pharmaceutical composition of claim 25 , wherein the cytotoxin is selected from the group consisting of biotoxins, chemotherapeutic agents, and radioisotopes.

27 . The pharmaceutical composition of claim 25 , wherein the cytotoxin is selected from the group consisting of maytansinoids, auristatins, duocarmycins, 225 Ac, 227 Th, and any derivatives thereof.

28 . The pharmaceutical composition of claim 25 , wherein the bispecific antigen-binding molecule is conjugated to a cytotoxic agent through a linker.

29 . The pharmaceutical composition of claim 28 , wherein the cytotoxic agent is a maytansinoid.

30 . The pharmaceutical composition of claim 29 , wherein the maytansinoid is:

wherein the - is the bond to the linker.

31 . The pharmaceutical composition of claim 30 , wherein the linker is:

wherein the bond noted with represents the bond to the bispecific antigen-binding molecule and the bond noted with represents the bond to the maytansinoid.

32 . The pharmaceutical composition of claim 29 , wherein the maytansinoid is

wherein the - is the bond to the linker.

33 . The pharmaceutical composition of claim 32 , wherein the linker is:

wherein the bond noted with represents the bond to the bispecific antigen-binding molecule and the bond noted with represents the bond to the maytansinoid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2024
From: BABB, ROBERT; CHEN, GANG; DALY, CHRISTOPHER; DASILVA, JOHN; MACDONALD, DOUGLAS; NITTOLI, THOMAS
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 066463/0129 →
Continuity (4)
Continuation 15814095 · Nov 15, 2017
Provisional Application 62479516 · Mar 31, 2017
Provisional Application 62423068 · Nov 16, 2016
Related Publication 20220049001A1 · Feb 17, 2022
References Cited (400)
US 5208020A · Chari et al. · 1993 [cited by applicant]
US 5639879A · Mease et al. · 1997 [cited by applicant]
US 5646036A · Schwall et al. · 1997 [cited by applicant]
US 5686292A · Schwall et al. · 1997 [cited by applicant]
US 5707624A · Nickoloff et al. · 1998 [cited by applicant]
US 5714586A · Kunstmann et al. · 1998 [cited by applicant]
US 6099841A · Hillan et al. · 2000 [cited by applicant]
US 6207152B1 · Schwall et al. · 2001 [cited by applicant]
US 6214344B1 · Schwall et al. · 2001 [cited by applicant]
US 6468529B1 · Schwall et al. · 2002 [cited by applicant]
US 7087411B2 · Daly et al. · 2006 [cited by applicant]
US 7476724B2 · Dennis et al. · 2009 [cited by applicant]
US 7498420B2 · Michaud et al. · 2009 [cited by applicant]
US 7556804B2 · Prat · 2009 [cited by applicant]
US 7615529B2 · Kong-Beltran et al. · 2009 [cited by applicant]
US 7714016B2 · Gangwar et al. · 2010 [cited by applicant]
US 7718174B2 · Chung et al. · 2010 [cited by applicant]
US 7750116B1 · Doronina et al. · 2010 [cited by applicant]
US 7754681B2 · Feng · 2010 [cited by applicant]
US 7892550B2 · Dennis et al. · 2011 [cited by applicant]
US 7892770B2 · Cao et al. · 2011 [cited by applicant]
US 8039598B2 · Cao · 2011 [cited by applicant]
US 8101727B2 · Stover et al. · 2012 [cited by applicant]
US 8133867B2 · Otsuka et al. · 2012 [cited by applicant]
US 8163280B2 · Michaud et al. · 2012 [cited by applicant]
US 8217148B2 · Davies et al. · 2012 [cited by applicant]
US 8309315B2 · Cao et al. · 2012 [cited by applicant]
US 8329173B2 · Goetsch · 2012 [cited by applicant]
US 8388958B2 · Comoglio et al. · 2013 [cited by applicant]
US 8398974B2 · Davies et al. · 2013 [cited by applicant]
US 8455623B2 · Van Der Horst et al. · 2013 [cited by applicant]
US 8501917B2 · Kim et al. · 2013 [cited by applicant]
US 8536118B2 · Kong-Beltran et al. · 2013 [cited by applicant]
US 8545839B2 · Goetsch et al. · 2013 [cited by applicant]
US 8546544B2 · Cheong et al. · 2013 [cited by applicant]
US 8562985B2 · Michaud et al. · 2013 [cited by applicant]
US 8563696B2 · Cheong et al. · 2013 [cited by applicant]
US 8623359B2 · Goetsch · 2014 [cited by applicant]
US 8637027B2 · Hultberg et al. · 2014 [cited by applicant]
US 8673302B2 · Goetsch et al. · 2014 [cited by applicant]
US 8741290B2 · Goetsch et al. · 2014 [cited by applicant]
US 8747850B2 · Goetsch et al. · 2014 [cited by applicant]
US 8765128B2 · Goetsch et al. · 2014 [cited by applicant]
US 8821869B2 · Michaud et al. · 2014 [cited by applicant]
US 8871909B2 · Goetsch · 2014 [cited by applicant]
US 8871910B2 · Goetsch · 2014 [cited by applicant]
US 8889832B2 · Goetsch · 2014 [cited by applicant]
US 8900582B2 · Cheong et al. · 2014 [cited by applicant]
US 9011865B2 · Goetsch · 2015 [cited by applicant]
US 9062104B2 · Garcia-Martinez et al. · 2015 [cited by applicant]
US 9068011B2 · Neijssen et al. · 2015 [cited by applicant]
US 9101610B2 · Cheong et al. · 2015 [cited by applicant]
US 9107907B2 · Goetsch · 2015 [cited by applicant]
US 9120852B2 · Jouhanneaud · 2015 [cited by applicant]
US 9150655B2 · Wu et al. · 2015 [cited by applicant]
US 9169329B2 · Johns et al. · 2015 [cited by applicant]
US 9192666B2 · Kim et al. · 2015 [cited by applicant]
US 9201074B2 · Davies et al. · 2015 [cited by applicant]
US 9213031B2 · Lee et al. · 2015 [cited by applicant]
US 9233155B2 · Kim et al. · 2016 [cited by applicant]
US 9249221B2 · Lee et al. · 2016 [cited by applicant]
US 9260531B2 · Beuerlein et al. · 2016 [cited by applicant]
US 9296817B2 · Kim et al. · 2016 [cited by applicant]
US 9328173B2 · Aldaz et al. · 2016 [cited by applicant]
US 9359437B2 · Davis et al. · 2016 [cited by applicant]
US 9364556B2 · Park et al. · 2016 [cited by applicant]
US 9375425B2 · Goetsch · 2016 [cited by applicant]
US 9394367B2 · Cheong et al. · 2016 [cited by applicant]
US 9458245B2 · Harms et al. · 2016 [cited by applicant]
US 9469691B2 · Cheong et al. · 2016 [cited by applicant]
US 9481725B2 · Dutzar et al. · 2016 [cited by applicant]
US 9487589B2 · Demeule et al. · 2016 [cited by applicant]
US 9505843B2 · Kim et al. · 2016 [cited by applicant]
US 9535055B2 · Kim et al. · 2017 [cited by applicant]
US 9556275B2 · Jeong et al. · 2017 [cited by applicant]
US 9567641B2 · Kim et al. · 2017 [cited by applicant]
US 9572878B2 · Lee et al. · 2017 [cited by applicant]
US 9580508B2 · Chiu et al. · 2017 [cited by applicant]
US 9593164B2 · Chiu et al. · 2017 [cited by applicant]
US 9631020B2 · Park et al. · 2017 [cited by applicant]
US 9631027B2 · Hultberg et al. · 2017 [cited by applicant]
US 9637541B2 · Kim et al. · 2017 [cited by applicant]
US 9650443B2 · Song et al. · 2017 [cited by applicant]
US 9657104B2 · Cho et al. · 2017 [cited by applicant]
US 9657107B2 · Neijssen et al. · 2017 [cited by applicant]
US 9688773B2 · Hultberg et al. · 2017 [cited by applicant]
US 9695228B2 · Mark et al. · 2017 [cited by applicant]
US 9717715B2 · Lee et al. · 2017 [cited by applicant]
US 9725497B2 · Anderson et al. · 2017 [cited by applicant]
US 9730926B2 · Lin et al. · 2017 [cited by applicant]
US 9732150B2 · Garcia-Martinez et al. · 2017 [cited by applicant]
US 9783603B2 · Garcia-Martinez et al. · 2017 [cited by applicant]
US 9808507B2 · Oh et al. · 2017 [cited by applicant]
US 9884917B2 · Hultberg et al. · 2018 [cited by applicant]
US 9902776B2 · Cho et al. · 2018 [cited by applicant]
US 9931400B2 · Jeong et al. · 2018 [cited by applicant]
US 9950076B2 · Nittoli et al. · 2018 [cited by applicant]
US 9975960B2 · Cho et al. · 2018 [cited by applicant]
US 9994644B2 · Wong et al. · 2018 [cited by applicant]
US 10000569B2 · Cheong et al. · 2018 [cited by applicant]
US 10100108B2 · Dutzar et al. · 2018 [cited by applicant]
US 10106622B2 · Yoo et al. · 2018 [cited by applicant]
US 10143749B2 · Cho et al. · 2018 [cited by applicant]
US 10214593B2 · Jung et al. · 2019 [cited by applicant]
US 10246507B2 · Lee et al. · 2019 [cited by applicant]
US 10570151B2 · Nittoli et al. · 2020 [cited by applicant]
US 11142578B2 · Babb et al. · 2021 [cited by applicant]
US 11896682B2 · Kelly et al. · 2024 [cited by applicant]
US 20040166544A1 · Morton et al. · 2004 [cited by applicant]
US 20050233960A1 · Kong-Beltran et al. · 2005 [cited by applicant]
US 20070258987A1 · Francisco et al. · 2007 [cited by applicant]
US 20070280945A1 · Stevens et al. · 2007 [cited by applicant]
US 20080305497A1 · Kosmeder et al. · 2008 [cited by applicant]
US 20090068179A1 · Nayeri et al. · 2009 [cited by applicant]
US 20090142354A1 · Papadopoulos et al. · 2009 [cited by applicant]
US 20090226443A1 · Filvaroff et al. · 2009 [cited by applicant]
US 20090226455A1 · Filvaroff · 2009 [cited by applicant]
US 20090297439A1 · Comoglio et al. · 2009 [cited by applicant]
US 20100016241A1 · Kong-Beltran et al. · 2010 [cited by applicant]
US 20100129314A1 · Singh et al. · 2010 [cited by applicant]
US 20100254988A1 · Bossenmaier et al. · 2010 [cited by applicant]
US 20100256339A1 · Bossenmaier et al. · 2010 [cited by applicant]
US 20110027286A1 · Thurston et al. · 2011 [cited by applicant]
US 20110104161A1 · Burgess et al. · 2011 [cited by applicant]
US 20110104166A1 · Stankovic et al. · 2011 [cited by applicant]
US 20110229469A1 · Johns · 2011 [cited by applicant]
US 20110239316A1 · Goetsch et al. · 2011 [cited by applicant]
US 20110287003A1 · Patel et al. · 2011 [cited by applicant]
US 20120134996A1 · Comoglio et al. · 2012 [cited by applicant]
US 20120171210A1 · Kong-Beltran et al. · 2012 [cited by applicant]
US 20120237524A1 · Boccaccio et al. · 2012 [cited by applicant]
US 20130089542A1 · Lee et al. · 2013 [cited by applicant]
US 20130101546A1 · Yurkovetskiy et al. · 2013 [cited by applicant]
US 20130102494A1 · Jouhanneaud · 2013 [cited by applicant]
US 20130109840A1 · Goetsch et al. · 2013 [cited by applicant]
US 20130129718A1 · Wong et al. · 2013 [cited by applicant]
US 20130143813A1 · Kirchhofer et al. · 2013 [cited by applicant]
US 20130156772A1 · Bossenmaier et al. · 2013 [cited by applicant]
US 20130164281A1 · Cheong et al. · 2013 [cited by applicant]
US 20130171063A1 · Johns et al. · 2013 [cited by applicant]
US 20130209365A1 · Wu et al. · 2013 [cited by applicant]
US 20130216548A1 · Neijssen et al. · 2013 [cited by applicant]
US 20130243775A1 · Papasopoulos et al. · 2013 [cited by applicant]
US 20130315895A1 · Farrell et al. · 2013 [cited by applicant]
US 20130316450A1 · Van Der Horst et al. · 2013 [cited by applicant]
US 20140349310A1 · Davies et al. · 2014 [cited by applicant]
US 20150017170A1 · Oh et al. · 2015 [cited by applicant]
US 20150050275A1 · Wong et al. · 2015 [cited by applicant]
US 20150182622A1 · Lashkari · 2015 [cited by applicant]
US 20150197542A1 · Kim et al. · 2015 [cited by applicant]
US 20150284808A1 · Chung et al. · 2015 [cited by applicant]
US 20150299326A1 · Wu et al. · 2015 [cited by applicant]
US 20160222115A1 · Huang et al. · 2016 [cited by applicant]
US 20160354482A1 · Nittoli · 2016 [cited by applicant]
US 20160375147A1 · Nittoli · 2016 [cited by applicant]
US 20170137539A1 · Fu et al. · 2017 [cited by applicant]
US 20170209591A1 · Nittoli et al. · 2017 [cited by applicant]
US 20170233489A1 · Shim et al. · 2017 [cited by applicant]
US 20170281796A1 · Zhu et al. · 2017 [cited by applicant]
US 20170283501A1 · Swanson et al. · 2017 [cited by applicant]
US 20170348429A1 · Reilly et al. · 2017 [cited by applicant]
US 20180110875A1 · Liu et al. · 2018 [cited by applicant]
US 20180134794A1 · Babb et al. · 2018 [cited by applicant]
US 20180250418A1 · Afar et al. · 2018 [cited by applicant]
US 20180280531A1 · Zhu et al. · 2018 [cited by applicant]
US 20180326085A1 · Doerner et al. · 2018 [cited by applicant]
US 20180327500A1 · Bouquin et al. · 2018 [cited by applicant]
US 20210077638A1 · Kelly et al. · 2021 [cited by applicant]
US 20220040319A1 · Schwartz et al. · 2022 [cited by applicant]
US 20240307563A1 · Kelly et al. · 2024 [cited by applicant]
EP 1636593B9 · 2009 [cited by applicant]
EP 2127683A1 · 2009 [cited by applicant]
EP 0922102B1 · 2010 [cited by applicant]
EP 1641828B1 · 2010 [cited by applicant]
EP 1773885B1 · 2010 [cited by applicant]
EP 2188312 · 2010 [cited by applicant]
EP 2316484 · 2011 [cited by applicant]
EP 1981981B1 · 2011 [cited by applicant]
EP 2336178A1 · 2011 [cited by applicant]
EP 2575879B1 · 2011 [cited by applicant]
EP 1997511B1 · 2011 [cited by applicant]
EP 2367008A2 · 2011 [cited by applicant]
EP 1957102B1 · 2012 [cited by applicant]
EP 2195345B1 · 2012 [cited by applicant]
EP 2004693B1 · 2012 [cited by applicant]
EP 2500036A1 · 2012 [cited by applicant]
EP 2535356 · 2012 [cited by applicant]
EP 2708556A1 · 2014 [cited by applicant]
EP 2787008A1 · 2014 [cited by applicant]
EP 1868648B1 · 2015 [cited by applicant]
EP 2358755 · 2015 [cited by applicant]
EP 2963058A1 · 2016 [cited by applicant]
EP 2635603B1 · 2016 [cited by applicant]
EP 2611928B1 · 2016 [cited by applicant]
EP 2635602B1 · 2016 [cited by applicant]
EP 2370468B1 · 2017 [cited by applicant]
EP 2824113B1 · 2017 [cited by applicant]
EP 2588497 · 2017 [cited by applicant]
EP 2870178B1 · 2017 [cited by applicant]
EP 3196211A1 · 2017 [cited by applicant]
EP 2786764B1 · 2017 [cited by applicant]
EP 2832748B1 · 2017 [cited by applicant]
EP 2784091B1 · 2017 [cited by applicant]
EP 2784092B1 · 2017 [cited by applicant]
EP 2467402B1 · 2018 [cited by applicant]
EP 2963058 · 2018 [cited by applicant]
EP 3284751A1 · 2018 [cited by applicant]
EP 2786765B1 · 2018 [cited by applicant]
EP 2415785 · 2018 [cited by applicant]
EP 2535357 · 2018 [cited by applicant]
EP 2764026B1 · 2018 [cited by applicant]
EP 3135691B1 · 2018 [cited by applicant]
EP 2545077B1 · 2018 [cited by applicant]
EP 2922566B1 · 2018 [cited by applicant]
EP 2922872B1 · 2018 [cited by applicant]
EP 2937421B1 · 2018 [cited by applicant]
EP 2708556B1 · 2018 [cited by applicant]
EP 2992019B1 · 2019 [cited by applicant]
EP 2764024A1 · 2019 [cited by applicant]
EP 3544634B1 · 2021 [cited by applicant]
JP 2009292815 · 2009 [cited by applicant]
JP 2022523360 · 2022 [cited by applicant]
WO WO2005016382A1 · 2005 [cited by applicant]
WO WO2005058965A1 · 2005 [cited by applicant]
WO WO2005089808 · 2005 [cited by applicant]
WO WO2006015371A2 · 2006 [cited by applicant]
WO WO2007064345A2 · 2007 [cited by applicant]
WO WO2008122039 · 2008 [cited by applicant]
WO WO2009111691A2 · 2009 [cited by applicant]
WO WO2009140549A1 · 2009 [cited by applicant]
WO WO2010010324 · 2010 [cited by applicant]
WO WO2010045344 · 2010 [cited by applicant]
WO WO2010045345 · 2010 [cited by applicant]
WO WO2010115551 · 2010 [cited by applicant]
WO WO2010115552 · 2010 [cited by applicant]
WO WO2010115553 · 2010 [cited by applicant]
WO WO2011018611 · 2011 [cited by applicant]
WO WO2011056983 · 2011 [cited by applicant]
WO WO2011110642A2 · 2011 [cited by applicant]
WO WO2011130598 · 2011 [cited by applicant]
WO WO2011143665 · 2011 [cited by applicant]
WO WO2011150454A1 · 2011 [cited by applicant]
WO WO2012003338 · 2012 [cited by applicant]
WO WO2012005982A2 · 2012 [cited by applicant]
WO WO2012136685 · 2012 [cited by applicant]
WO WO2012161372 · 2012 [cited by applicant]
WO WO2012165925 · 2012 [cited by applicant]
WO WO2012166559 · 2012 [cited by applicant]
WO WO2013003680A1 · 2013 [cited by applicant]
WO WO2013043452 · 2013 [cited by applicant]
WO WO2013043715 · 2013 [cited by applicant]
WO WO2013045707A2 · 2013 [cited by applicant]
WO WO2013051891 · 2013 [cited by applicant]
WO WO2013053872 · 2013 [cited by applicant]
WO WO2013053873 · 2013 [cited by applicant]
WO WO2013055990 · 2013 [cited by applicant]
WO WO2013055993 · 2013 [cited by applicant]
WO WO2013064701A2 · 2013 [cited by applicant]
WO WO2013068874 · 2013 [cited by applicant]
WO WO2013081379 · 2013 [cited by applicant]
WO WO2013085925 · 2013 [cited by applicant]
WO WO2013152252A1 · 2013 [cited by applicant]
WO WO2013169532A1 · 2013 [cited by applicant]
WO WO2013188752 · 2013 [cited by applicant]
WO WO2013192594 · 2013 [cited by applicant]
WO WO2014065661A1 · 2014 [cited by applicant]
WO WO2014081944 · 2014 [cited by applicant]
WO WO2014081954 · 2014 [cited by applicant]
WO WO2014145090A1 · 2014 [cited by applicant]
WO WO2015031396A1 · 2015 [cited by applicant]
WO WO2015081857A1 · 2015 [cited by applicant]
WO WO2015140212A1 · 2015 [cited by applicant]
WO WO2016042412A1 · 2016 [cited by applicant]
WO WO2016060297 · 2016 [cited by applicant]
WO WO2016085820 · 2016 [cited by applicant]
WO WO2016094455A1 · 2016 [cited by applicant]
WO WO2016149265A1 · 2016 [cited by applicant]
WO WO2016160615A1 · 2016 [cited by applicant]
WO WO2017076492A1 · 2017 [cited by applicant]
WO WO2017087603A1 · 2017 [cited by applicant]
WO WO2017132173A1 · 2017 [cited by applicant]
WO WO2017135791A1 · 2017 [cited by applicant]
WO WO2017201204A1 · 2017 [cited by applicant]
WO WO2018050733A1 · 2018 [cited by applicant]
WO WO2018068758 · 2018 [cited by applicant]
WO WO2018069851 · 2018 [cited by applicant]
WO WO2018093866A1 · 2018 [cited by applicant]
WO WO2018098035A1 · 2018 [cited by applicant]
WO WO2018221969A1 · 2018 [cited by applicant]
WO WO2018223958A1 · 2018 [cited by applicant]
WO WO2018232349A1 · 2018 [cited by applicant]
WO WO2019031965A1 · 2019 [cited by applicant]
WO WO2019066617 · 2019 [cited by applicant]
WO WO2019066620 · 2019 [cited by applicant]
WO WO2020172475A1 · 2020 [cited by applicant]
WO WO2022171115A1 · 2022 [cited by applicant]
Agarwal et al., (2013) “A Pictet-Spengler Ligation for Protein Chemical Modification”, Proc. Natl. Acad. Sci., USA, 110:46-51. [cited by applicant]
AL-Lazikaniet al., (1997) “Standard Conformations for the Canonical Structures of Immunoglobulins”, J. Mol. Biol. 273:927-948. [cited by applicant]
Allen (1999) “The Art, Science and Technology of Pharmaceutical Compounding”, Fifth Edition, American Pharmacists Association, Washington D.C. [cited by applicant]
Altschul et al., (1990) “Basic Local Alignment Search Tool”, J. Mol. Biol. 215:403-410. [cited by applicant]
Altschul et al., (1997) “Grapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Res. 25:3389-402. [cited by applicant]
Andres et al. (2019) “Inhibition of the MET Kinase Activity and Cell Growth in METAddicted Cancer Cells by Bi-Paratopic Linking” Journal of Molecular Biology, 40 pages. [cited by applicant]
Bancroft et al., (1986) “Regulation of macrophage la expression in mice with severe combined immunodeficiency: induction of la expression by a T cell-independent mechanism”, J. Immunol. 137(1): 4-9, 1986. [cited by applicant]
Bean et al., (2007) “MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib,” Proc. Natl. Acad. Sci., 104(52): 20932-20937. [cited by applicant]
Boersma and Pluckhun (2011) “DARPins and other repeat protein scaffolds: advances in engineering and applications”, Curr. Opin. Biotechnol. 22:849-857. [cited by applicant]
Camidge et al. (2018) “An Open-Label, Multicenter, Phase 1 Study of ABBV-399 (Telisotuzumab Vedotin, Teliso-V) as Monotherapy (T) and in Combination With Erlotinib (T+E) in Non-Small Cell Lung Cancer (NSCLC)” Presented … [cited by applicant]
Carrico et al., (2007) “Introducing genetically encoded aldehydes into proteins”, Nat. Chem. Biol., 3:321-322. [cited by applicant]
Casi et al. (2012) “Antibody-drug conjugates: Basic concepts, examples and future perspectives”, Journal of Controlled Release 161:422-428. [cited by applicant]
Cheng et al. (2018) “Phase 2 Study of Tepotinib + Gefitinib in MET-Positive/Epidermal Growth Factor Receptor-Mutant NSCLC”, Munich 2018 ESMO Congress, 15 pages. [cited by applicant]
Cho et al. (2018) “JNJ-61186372 (JNJ-372), an EGFR-cMET Bispecific Antibody, in Advanced Non-Small Cell Lung Cancer (NSCLC): An Update on Phase 1 Results” Presented at the 43rd Annual Congress of the European Society fo… [cited by applicant]
Collins (2007) “ImageJ for microscopy”, BioTechniques 43: S25-S30. [cited by applicant]
Czyz (2018) “HGF/c-MET Signaling in Melanocytes and Melanoma”, International Journal of Molecular Sciences, 19(12):3844-3856. [cited by applicant]
Dinter et al., (2015) “Inverse Agonistic Action of 3-lodothyronamine at the Human Trace Amine-Associated Receptor 5”, PLoS One 10(2): e0117774. [cited by applicant]
Doronina et al., (2003) “Development of potent monoclonal antibody auristatin conjugates for cancer therapy”, Nature Biotechnology, 21(7):778-784. [cited by applicant]
Ducry (2010) “Antibody—Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies”, Bioconjugate Chem., 21:5-13. [cited by applicant]
Ducry (2013) “Antibody-Drug Conjugates” Humana Press, Springer Protocols, 315 pages. [cited by applicant]
Ehring (1999) “Hydrogen Exchange/Electrospray Ionization Mass Spectrometry Studies of Structural Features of Proteins and Protein/Protein Interactions”, Analytical Biochemistry 267(2):252-259. [cited by applicant]
Engen and Smith (2001) “The Basics of Ion Chromatography”, Anal. Chem. 73:256A-265A. [cited by applicant]
Ferrucci, et al. (2014) “A HGF/Cmet Autocrine Loop is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target”, Cancer Research, 20:5796-5807. [cited by applicant]
Godar, et al. (2016) “Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy”, Scientific Reports, 6:31621; 1-12, DOI:10.1038/srep31621. [cited by applicant]
Gonnet et al., (1992) “Exhaustive Matching of the Entire Protein Sequence Database”, Science 256: 1443-1445. [cited by applicant]
Grandal et al. (2017) “Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms”, Molecular Cancer Therapeutics, 16:2780-2791. [cited by applicant]
Greenall, et al. (2012) “Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET”, PLOS One, Public Library of Science, US, 7(4):E34658.1-E34… [cited by applicant]
Hamblett et al., (2004) “Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate”, American Association for Cancer Research, 10(20):7063-7070. [cited by applicant]
Han et al. (2017) “Analysis of Progress and Challenges for Various Patterns of c-MET-targeted Molecular Imaging: a Systematic Review”, Ejnmmi Research, Biomed Central Ltd., 7(1):1-15. [cited by applicant]
Hochleitner et al., (2000) “Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometri… [cited by applicant]
Hofer et al., (2008) “An engineered selenocysteine defines a unique class of antibody derivatives”, Proc. Natl. Acad. Sci., USA, 105:12451-12456. [cited by applicant]
Hollander et al., (2008) “Selection of Reaction Additives Used in the Preparation of Monomeric Antibody-Calicheamicin Conjugates”, Bioconjugate Chem., 19:358-361. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/050865 dated Dec. 1, 2020, 19 pages. [cited by applicant]
International Search Report and Written Opinion, received for PCT/US2017/061757 on Apr. 4, 2018, 22 pages. [cited by applicant]
International Search Report and Written Opinion, for International Application No. PCT/US2020/019126 dated Jun. 18, 2020, 16 pages. [cited by applicant]
Jeger et al. (2010) “Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase”, Angew Chemie Inter Ed. 49:9995-9997. [cited by applicant]
Junghans et al., (1990) “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders”, Cancer Research 50:14951502. [cited by applicant]
Kabat, (1991) “Sequences of Proteins of Immunological Interest”, National Institutes of Health, Bethesda, Md. [cited by applicant]
Kawakami et al. (2014) “Targeting MET Amplification as a New Oncogenic Driver”, Cancers 6:1540-1552. [cited by applicant]
Kazane et al. (2013) “Self-Assembled Antibody Multimers through Peptide Nucleic Acid Conjugation”, J Am Chem Soc 135:340-346. [cited by applicant]
Kazane et al., (2012) “Self-Assembled Antibody Multimers through Peptide Nucleic Acid Conjugation”, J. Am. Chem. Soc. [Epub: Dec. 4, 2012]. [cited by applicant]
Klein et al., (2012) Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies, mAbs 4:6, 1-11. [cited by applicant]
Ku and Park (2005) “Biology of SNU cell lines”, Cancer Res. Treat. 37(1): 1-19. [cited by applicant]
Kubo et al., (2009) “MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors”, Int. J. Cancer, 124(8): 1778-1784. [cited by applicant]
Liu, et al. (2014) “LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth”, Clinical Cancer Research 20(23):6059-6070. [cited by applicant]
Lutterbach et al., (2007) “Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival”, Cancer Res. 67(5):2081-2088. [cited by applicant]
Martens et al. (2006) “A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo”, Clin Cancer Res, 12(20): 6144-6152. [cited by applicant]
Martin et al., (1989) “Modeling antibody hypervariable loops: A combined algorithm”, Proc. Natl. Acad. Sci. USA 86:9268-9272. [cited by applicant]
Nair et al., (1994) “Induction of squamous differentiation by interferon beta in a human non-small-cell lung cancer cell line”, J. Nat'l. Cancer Inst. 86(5): 378-383. [cited by applicant]
Nakamura et al. (2010) “The discovery of Hepatocyte Growth Factor (HGF) and its significance for cell biology, life sciences and clinical medicine”, Proc. Jpn. Acad., Ser. B 86:588. [cited by applicant]
Olopade et al., (1992) “Molecular Analysis of Deletions of the Short Arm of Chromosome 9 in Human Gliomas”, Cancer Research 52: 2523-2529. [cited by applicant]
Padlan et al. (1995) “Identification of Specificity-Determining Residues in Antibodies”, FASEB J. 9(1):133-139. [cited by applicant]
Pearson (1994) “Using the FASTA Program to Search Protein and DNA Sequence Database”, Methods Mol. Biol. 24: 307-331. [cited by applicant]
Pearson (2000) “Flexible Sequence Similarity Searching with the FASTA3 Program Package”, Methods in Molecular Biology, 132:185-219. [cited by applicant]
Powell et al. (1998) “Compendium of excipients for parenteral formulations” PDA J Pharm Sci Technol 52:238-311. [cited by applicant]
Rabuka et al., (2012) “Site-specific chemical protein conjugation using genetically encoded aldehyde tags”, Nat. Protocols, 10:1052-1067. [cited by applicant]
Reineke, (2004) “Antibody Epitope Mapping Using Arrays of Synthetic Peptides”, Methods Mol Biol 248:443-463. [cited by applicant]
Rock, et al. (2015) “Intracelluar Catabolism of an Antibody Drug Conjugate with a Noncleavable Linker”, Drug Metabolism and Disposition, 43:1341-1344. [cited by applicant]
Rosen et al., (2017) “A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer”, Clin. Cancer Res., 23(8):1910-1919. [cited by applicant]
Ryan et al., (2001) “Polyclonal Antibody Production Against Chito-Oligosaccharides”, Food & Agriculture Immunol., 13:127-130. [cited by applicant]
Sameer, et al. (2012) “Non-agonistic bivalent antibodies that promote c-Met degradation and inhibit tumor growth and others specific for tumor related c-Met”, Plos One, Public Library of Science, US, 7(4):e34658.1-e3465… [cited by applicant]
Sapra et al., (2013) “Monoclonal antibody-based therapies in cancer: Advances and challenges”, Pharmacol. & Therapeutics, 138:452-469. [cited by applicant]
Schumacher et al. (2016) “Current Status: Site-Specific Antibody Drug Conjugates”, J. Clin. Immunol. 36(Suppl 1):100-107. [cited by applicant]
Shaunak et al., (2006) “Site-specific PEGylation of native disulfide bonds in therapeutic proteins,” Nat. Chem. Biol., 2:312-313. [cited by applicant]
Shields et al., (2002) “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcyRIII and Antibody-dependent Cellular Toxicity,” JBC 277:26733. [cited by applicant]
Sierra and Tsao (2011) “c-MET as a potential therapeutic target and biomarker in cancer”, Ther. Adv. Med. Oncol., 3(1 Suppl): S21-S35. [cited by applicant]
Smith (1979) “In Vitro Properties of Epithelial Cell Lines Established from Human Carcinomas and Nonmalignant Tissue”, J. Nat'l. Cancer Inst. 62(2): 225-230. [cited by applicant]
Surriga, et al. (2013) “Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model”, Molecular Cancer Therapeutics, 12(12):2817-2826. [cited by applicant]
Taylor et al. (1992) “A Transgenic mouse that expresss a diversity of human sequence heavy and light chain immunoglobulins”, Nucl. Acids Res. 20:6287-6295. [cited by applicant]
Taylor et al. (2017) “AbbVie pairs up another ADC cancer drug with Bristol-Myers Squibb's Opdvio” FierceBiotech. https://www.fiercebiotech.com/biotech/abbvie-pairs-up-another-adc-cancer-drug-bms-opdivo. [cited by applicant]
Tomer (2000) “Characterization of a Discontinuous Epitope of the Human Immunodeficiency Virus (HIV) Core Protein p24 by Eptiope Excision and Differential Chemical Modification Followed by Mass Spectrometric Peptide Mapp… [cited by applicant]
Tsao et al. (2001) “Hepatocyte Growth Factor is Predominantly Expressed by the Carcinoma Cells in Non-Small-Cell Lung Cancer”, Human Pathology 32(1):57-65. [cited by applicant]
Vajdos et al. (2002) “Comprehensive Functional Maps of the Antigen-Binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis”, J Mol Biol, 320:415-428. [cited by applicant]
Vordermark and Brown, (2003) “Evaluation of hypoxia-inducible factor-1α (HIF-1α) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: In vitro and xenograft studies”, Int. J. Radiation Biol. 56(4): 1184… [cited by applicant]
Wang et al. (2016) “ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence”, Clinical Cancer Research, 23(4):992-1000. [cited by applicant]
Wang et al. (2016) “Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplicfication”, BMC Cancer 16:105, pp. 1-14. [cited by applicant]
Widdison et al. (2006) “Semisynthetic maytansine analogues for the targeted treatment of cancer”, J. Med. Chem., 49(14):4392-4408. [cited by applicant]
Wolf, et al. (2018) “Results of The Geometry Mono-1 Phase Ii Study For Evaluation of The Met Inhibitor Capmatinib (INC280) in Patients With MetΔex14 Mutated Advanced Non-Small Cell Lung Cancer” Munich 2018 ESMO Congress… [cited by applicant]
Xiang et al., (2013) “Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration—Effect Data to Support Clinical Development”, Clin. Cancer Res. 19(18): 5068-5078. [cited by applicant]
DiCara et al. (2017) “Characterization and Structural Determination of a New Anti-MET Function-Blocking Antibody with Binding Epitope Distinct From the Ligand Binding Domain,” Sci. Reports, 7:9000 pp. 1-13 and Supplemen… [cited by applicant]
DeSole et al. (2021) “Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor”, Frontiers in Immunology, vol. 12, Article 775151. [cited by applicant]
Esmaeli et al. (2009) “GPNMB Expression in Uveal Melanoma: a Potential for Targeted Therapy,” Melanom Res., 20(3):184-190. [cited by applicant]
Fleury et al. (2000) “Structural Evidence for Recognition of a Single Epitope by Two Distinct Antibodie”, Structure Function, and Genetics, 40:572-578. [cited by applicant]
Freise et al. (2015) “In Vivo imaging with Antibodies and Engineered Fragments”, Molecular Immunology, Pergamon, 67(2):142-152. [cited by applicant]
Gherardi et al. (2003) “Functional Map and Doman Structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor scatter factor”, PNAS, 100(21):12039-12044. [cited by applicant]
Jain et al. (2015) “Current ADC Linker Chemistry”, Pharm. Res., 1-15. [cited by applicant]
Jagoda et al. (2012) “Immuno-PET of the Hepatocyte Growth Factor Receptor Met Using he 1-Armed Antibody Onartuzumab”, The Journal of Nuclear Medicine, 53(10):1562-1600. [cited by applicant]
Nehoff, et al. (2015) “A Combination of Tyrosine Kinase Inhibitors, Crizotinib and Dasatinib for the Treatment of Glioblastoma Multiforme,” Oncotarget, 6(35):37948-37964. [cited by applicant]
Perk et al. (2008) “Quantitative PET Imaging of Met-expressing Human Cancer Xenografts with 89Zr-labelled Monoclonal Antibody DN30”, European Journal of Nuclear Medicine and Molecular Imaging, 35(10):1857-1867. [cited by applicant]
Perk et al. (2008) “Facile Radiolabeling of Monoclonal Antibodies and Other Proteins with Zirconium-89 or Gallium-68 for PET Imaging Using P-isothiocyanatoenzyl-desferrioxamine”, Protocol Exchange, XP055750961. [cited by applicant]
Prat et al. (2014) “Monoclonal Antibodies Against the MET/HGF Receptor and it's Ligand: Multitask Tools with Applications from Basic Research to Therapy,” Biomedicines, 2:359-383. [cited by applicant]
Raybould et al. (2021) “Public Baseline and Shared Response Structures Support the Theory of Antibody Repertoire Functional Commonality”, PNAS, 116(10):4025-4030. [cited by applicant]
Wong, et al. (2021) “Ab-Ligity: Identifying Sequence-Dissimilar Antibodies That Bind to the Same Epitope”, mAbs, 13(1):1-8. [cited by applicant]
Phillips (2008) “Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate,” Cancer Res., 68:9280-9290. [cited by applicant]
Bendig (1995) “Humanization of Rodent Monoclonal Antibodies by CDR Grafting,” Methods: A Companion to Methods in Enzymology, 8: 83-93. [cited by applicant]
Casset, et al. (2003) “A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design,” Biochemical and Biophysical Research Communications, 307:198-205. [cited by applicant]
Chen, et al. (1995) “Enhancement and Destructions of Antibody Function by Somatic Mutation: Unequal Occurrence is Controlled by V Gene Combinatorial Associations,” The EMBO Journal, 14(12):2784-2794. [cited by applicant]
Colman (1994) “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,” Research in Immunology, Elsevier, NY, 145(1):33-36. [cited by applicant]
Maccallum, et al. (1996) “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol., 262:732-745. [cited by applicant]
Paul (1993) “Fundamental Immunology,” Third Edition, Raven Press, NY, Chapter 9, pp. 292-295. [cited by applicant]
Rudikoff, et al. (1982) “Single Amino Acid Substitution Altering Antigen-Binding Specificity,” Proc. Natl. Acad. Sci. USA, 79:1979-1983. [cited by applicant]
Fan, et al. (2015) “Bispecific Antibodies and Their Applications”, J. Hematology & Oncology, 8:130, 14 pages. [cited by applicant]
Gstöttner, et al. (2020) “Intact and Subunit-Specific Analysis of Bispecific Antibodies by Sheathless CE-MS”, Analytica Chimica Acta, 1134:18-27. [cited by applicant]
Abdel-Rahman et al., (2007) “The High Frequency of cMET Over-Expression in Uveal Melanoma is Likely Through Altered Gene Regulation Rather Than Mutation and Amplification of the cMET Gene,” Invest. Ophthalmol. Vis. Sci.… [cited by applicant]